Lab testing, Consulting, & Services
2730 Monterey Street, Suite 104, Torrance, CA 90503
Tel: 424 488 2221; e-mail: Quality@progressivegmp.com



CERTIFICATE OF ANALYSIS

Sample Description: CBD CLINIC™ Level 02 Pain Relief Cream 110kg, CBD	Quote/PO Reference:
	Customer: Aidance
Batch/Lot: V0321027	Date of Receipt: 01/28/2021
SKU/Identification Number: M-2996	Date of Testing: 01/28/2021
Accession Number: 21-16810	Date of Report: 02/02/2021

Test Name	Method	Results
CBD Assay	AOAC SMPR 2017.001 & 2017.002 or AHP or equivalent, modified	3.10 mg/g
THC (Δ-9-THC)	AOAC SMPR 2017.001 & 2017.002 or AHP or equivalent, modified	<0.1%

Test procedures and methods used for testing are per method referenced above. Modification of test method may be done suitability to sample matrix.

Comments (if any): > 2.25 mg/g

02/02/2021

Laboratory In-charge/Director Prashant Ingle





Lab testing, Consulting, & Services
2730 Monterey Street, Suite 104, Torrance, CA 90503
Tel: 424 488 2221; e-mail: Quality@progressivegmp.com



CERTIFICATE OF ANALYSIS

Sample Description: CBD CLINIC™ Level 02 Pain Relief Cream 44g, FP Assay Beg	Quote/PO Reference:
	Customer: Aidance
Batch/Lot: V0321027	Date of Receipt: 02/10/2021
SKU/Identification Number: F-2996	Date of Testing: 02/10/2021
Accession Number: 21-17182	Date of Report: 02/15/2021

Test Name	Method	Results
Camphor	USP or AOAC or equivalent (modified)	3.3 %

Test procedures and methods used for testing are per method referenced above. Modification of test method may be done suitability to sample matrix.

Comments (if any): Camphor 3% (2.7% – 3.3%) composite of all beg samples

02/15/2021

Laboratory In-charge/Director Prashant Ingle





Lab testing, Consulting, & Services
2730 Monterey Street, Suite 104, Torrance, CA 90503
Tel: 424 488 2221; e-mail: Quality@progressivegmp.com



CERTIFICATE OF ANALYSIS

Sample Description: CBD CLINIC™ Level 02 Pain Relief Cream 44g, FP Assay Mid	Quote/PO Reference:
	Customer: Aidance
Batch/Lot: V0321027	Date of Receipt: 02/10/2021
SKU/Identification Number: F-2996	Date of Testing: 02/10/2021
Accession Number: 21-17183	Date of Report: 02/15/2021

Test Name	Method	Results
Camphor	USP or AOAC or equivalent (modified)	3.3 %

Test procedures and methods used for testing are per method referenced above. Modification of test method may be done suitability to sample matrix.

Comments (if any): Camphor 3% (2.7% - 3.3%) composite of all mid samples

02/15/2021

Laboratory In-charge/Director Prashant Ingle





Lab testing, Consulting, & Services
2730 Monterey Street, Suite 104, Torrance, CA 90503
Tel: 424 488 2221; e-mail: Quality@progressivegmp.com



CERTIFICATE OF ANALYSIS

Sample Description: CBD CLINIC™ Level 02 Pain Relief Cream 44g, FP Assay End	Quote/PO Reference:
	Customer: Aidance
Batch/Lot: V0321027	Date of Receipt: 02/10/2021
SKU/Identification Number: F-2996	Date of Testing: 02/10/2021
Accession Number: 21-17184	Date of Report: 02/15/2021

Test Name	Method	Results
Camphor	USP or AOAC or equivalent (modified)	3.2 %

Test procedures and methods used for testing are per method referenced above. Modification of test method may be done suitability to sample matrix.

Comments (if any): Camphor 3% (2.7% – 3.3%) composite of all end samples

02/15/2021

Laboratory In-charge/Director Prashant Ingle





Lab testing, Consulting, & Services
2730 Monterey Street, Suite 104, Torrance, CA 90503
Tel: 424 488 2221; e-mail: Quality@progressivegmp.com



CERTIFICATE OF ANALYSIS

Sample Description: CBD CLINIC™ Level 02 Pain Relief Cream 44g, FP Micro	Quote/PO Reference:
	Customer: Aidance
Batch/Lot: V0321027	Date of Receipt: 02/10/2021
SKU/Identification Number: F-2996	Date of Testing: 02/10/2021
Accession Number: 21-17185	Date of Report: 02/15/2021

Test Name	Method	Results
Total Aerobic Microbial Count (TAMC/APC)	USP61 (modified)	<10 cfu/g or mL
Total Combined Yeasts and Molds Count (TYMC)	USP61 (modified)	<10 cfu/g or mL
Staphylococcus aureus	USP62 (modified)	Absent /g or mL
Pseudomonas aeruginosa	USP62 (modified)	Absent /g or mL

Test procedures and methods used for testing are per method referenced above. Modification of test method may be done suitability to sample matrix.

Comments (if any): composite of all samples

02/15/2021	

Laboratory In-charge/Director Prashant Ingle

Inglefall



